Published in Dig Dis Sci on July 01, 1997
Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut (2002) 1.94
Inflammation and proliferation act together to mediate intestinal cell fusion. PLoS One (2009) 1.18
Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol (2010) 1.10
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis (2003) 1.06
Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin Exp Immunol (2000) 1.06
Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut (2000) 1.06
Effects of the macrolide drug tylosin on chronic diarrhea in rhesus macaques (Macaca mulatta). Comp Med (2008) 1.04
Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chem Biol (2013) 0.95
Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation (2001) 0.93
Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol (1998) 0.93
Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm (2014) 0.92
Tumor necrosis factor-alpha impairs intestinal phosphate absorption in colitis. Am J Physiol Gastrointest Liver Physiol (2009) 0.90
Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol (2010) 0.87
Reduced expression of aquaporins in human intestinal mucosa in early stage inflammatory bowel disease. Clin Exp Gastroenterol (2015) 0.84
Lidocaine inhibits secretion of IL-8 and IL-1beta and stimulates secretion of IL-1 receptor antagonist by epithelial cells. Clin Exp Immunol (2002) 0.81
Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection. Front Immunol (2015) 0.80
Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4(+) T Cells. Biomed Res Int (2015) 0.80
Butyrate enhancement of inteleukin-1β production via activation of oxidative stress pathways in lipopolysaccharide-stimulated THP-1 cells. J Clin Biochem Nutr (2011) 0.77
Induction and cellular expression of tartrate resistant acid phosphatase during dextran sodium sulphate induced colitis in rats. Histochem Cell Biol (2009) 0.75
IL-1β-Induced Downregulation of the Multifunctional PDZ Adaptor PDZK1 Is Attenuated by ERK Inhibition, RXRα, or PPARα Stimulation in Enterocytes. Front Physiol (2017) 0.75
Tumor necrosis factor signaling is implicated in intestinal mucosal injury of cancer cachexic mice. Onco Targets Ther (2012) 0.75
CD137 signaling enhances tight junction resistance in intestinal epithelial cells. Physiol Rep (2014) 0.75
Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention. Nutrients (2017) 0.75
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A (1989) 15.69
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 11.95
A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques (1993) 9.61
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (1992) 6.66
Competitive PCR. Nature (1992) 5.96
Inflammatory bowel disease (1) N Engl J Med (1991) 5.78
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut (1989) 4.59
Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology (1994) 3.60
Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 3.25
Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology (1993) 3.20
Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. Gut (1990) 3.18
Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology (1992) 3.04
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 2.98
Short-term course and prognosis of Crohn's disease. Gut (1974) 2.90
Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology (1994) 2.85
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47
Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. Nucleic Acids Res (1988) 2.15
Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am (1995) 2.14
Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell (1993) 1.99
Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology (1992) 1.98
PCR MIMICS: competitive DNA fragments for use as internal standards in quantitative PCR. Biotechniques (1993) 1.89
Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology (1992) 1.79
Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology (1993) 1.75
Tumor necrosis factor and IL-1 beta expression in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (1993) 1.65
The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am (1992) 1.59
Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology (1994) 1.45
Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease. Gastroenterology (1994) 1.41
Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut (1992) 1.39
Cells and cytokines in mucosal immunity and inflammation. Gastroenterol Clin North Am (1992) 1.30
T-cell activation can induce either mucosal destruction or adaptation in cultured human fetal small intestine. Gastroenterology (1993) 1.29
Cytokine mRNA expression in intestine from normal and inflammatory bowel disease patients. Clin Immunol Immunopathol (1993) 1.25
Primers are decisive for sensitivity of PCR. Biotechniques (1994) 1.17
Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells. J Virol (1990) 1.09
Pathogenesis of ulcerative colitis. Lancet (1993) 1.07
Determining transcript number using the polymerase chain reaction: Pgk-2, mP2, and PGK-2 transgene mRNA levels during spermatogenesis. Nucleic Acids Res (1991) 1.03
Immunopathogenesis of chronic inflammatory bowel disease. Acta Paediatr Suppl (1994) 1.02
Direct quantification of picomolar concentrations of mRNAs by mathematical analysis of a reverse transcription/exponential polymerase chain reaction assay. Nucleic Acids Res (1992) 0.99
Measurement of tumor necrosis factor alpha mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg Immunol (1993) 0.96
Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (1991) 0.95
Polymerase chain reaction-based mRNA quantification using an internal standard: analysis of oncogene expression. Methods Enzymol (1993) 0.92
Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions (1991) 0.91
Cytokines in inflammatory bowel disease. Scand J Gastroenterol (1992) 0.91
Absolute levels of mRNA by polymerase chain reaction-aided transcript titration assay. Methods Enzymol (1993) 0.85
Interleukin-2 activity of colonic lamina propria mononuclear cells in a rat model of experimental colitis. Gastroenterology (1993) 0.84
Quantitative PCR for detection of femtogram quantities of interleukin-8 mRNA expression. Microbiol Immunol (1994) 0.82
Quantitative evaluation of gene expression in freshly isolated human respiratory epithelial cells. Am J Physiol (1993) 0.79
Improved quantification with validation of multiple mRNA species by polymerase chain reaction: application to human myocardial creatine kinase M and B. Cardiovasc Res (1994) 0.77
Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy? Gut (1994) 0.75
Taq polymerase (EC 2.7.7.7): with particular emphasis on its use in PCR protocols. Methods Mol Biol (1993) 0.75
Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol (1998) 7.43
Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci U S A (1994) 4.53
The growing family of interferon regulatory factors. Cytokine Growth Factor Rev (1997) 3.33
Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem (1998) 3.31
Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription. Mol Cell Biol (1999) 3.12
Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol Cell Biol (2000) 3.00
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
Interferon regulatory factors: the next generation. Gene (1999) 2.98
Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol Cell Biol (1999) 2.93
Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc Natl Acad Sci U S A (1998) 2.69
Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3. J Biol Chem (2001) 2.47
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
Multiple regulatory domains control IRF-7 activity in response to virus infection. J Biol Chem (2000) 2.20
The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol (2000) 2.13
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12
Regulation of RANTES chemokine gene expression requires cooperativity between NF-kappa B and IFN-regulatory factor transcription factors. J Immunol (2000) 2.02
Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology (1993) 1.94
HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene (2001) 1.94
Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. Mol Cell Biol (1996) 1.90
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 1.86
Differential expression of human interferon genes. Nucleic Acids Res (1984) 1.82
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis (2001) 1.77
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Effectiveness of antigliadin antibodies as a screening test for celiac disease in children. CMAJ (1997) 1.59
Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res (2001) 1.57
Distinct patterns of cow's milk allergy in infancy defined by prolonged, two-stage double-blind, placebo-controlled food challenges. Clin Exp Allergy (1996) 1.51
Viral induction of the human beta interferon promoter: modulation of transcription by NF-kappa B/rel proteins and interferon regulatory factors. J Virol (1994) 1.51
Synergism between distinct enhanson domains in viral induction of the human beta interferon gene. Mol Cell Biol (1990) 1.46
Mutational analysis of interferon (IFN) regulatory factors 1 and 2. Effects on the induction of IFN-beta gene expression. J Biol Chem (1994) 1.45
Soluble Fas and soluble Fas-ligand in children with Escherichia coli O157:H7-associated hemolytic uremic syndrome. Am J Kidney Dis (2000) 1.39
Amplification and rearrangement of integrated SV40 DNA sequences accompany the selection of anchorage-independent transformed mouse cells. Cell (1980) 1.38
Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell Mol Biol (Noisy-le-grand) (2006) 1.33
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.32
Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology (2000) 1.32
I kappaB alpha physically interacts with a cytoskeleton-associated protein through its signal response domain. Mol Cell Biol (1997) 1.31
Interferon activation and innate immunity. Rev Immunogenet (2000) 1.31
Multiple protein-DNA interactions within the human interferon-beta regulatory element. J Biol Chem (1989) 1.28
Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth. Biochimie (1999) 1.26
Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. J Biol Chem (1998) 1.23
Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol (2001) 1.23
Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut (2003) 1.23
Successful videocapsule endoscopy in patients with an abdominal cardiac pacemaker. Endoscopy (2007) 1.19
Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol (2001) 1.17
Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev (1996) 1.17
Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol (1996) 1.16
Differential transcriptional activation in vitro by NF-kappa B/Rel proteins. J Biol Chem (1995) 1.15
Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity (2000) 1.15
IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene (2000) 1.14
Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn's disease. Aliment Pharmacol Ther (2009) 1.13
Nuclear IkappaBbeta maintains persistent NF-kappaB activation in HIV-1-infected myeloid cells. J Biol Chem (1999) 1.12
Overproduction of NFKB2 (lyt-10) and c-Rel: a mechanism for HTLV-I Tax-mediated trans-activation via the NF-kappa B signalling pathway. Oncogene (1994) 1.12
Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol (1991) 1.11
Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication. J Virol (1996) 1.11
Cell-specific differences in activation of NF-kappa B regulatory elements of human immunodeficiency virus and beta interferon promoters by tumor necrosis factor. J Virol (1990) 1.10
Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells. J Virol (1990) 1.09
Modulatory effects of Epstein-Barr, herpes simplex, and human herpes-6 viral infections and coinfections on cytokine synthesis. A comparative study. J Immunol (1992) 1.09
Dientamoeba fragilis masquerading as allergic colitis. J Pediatr Gastroenterol Nutr (1998) 1.09
Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line. J Biol Chem (2001) 1.09
Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Oncogene (1997) 1.09
IkappaB-mediated inhibition of virus-induced beta interferon transcription. J Virol (1999) 1.09
A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol Cell Biochem (1999) 1.08
Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP). Cell Death Differ (1999) 1.08
Chronic human immunodeficiency virus type 1 infection stimulates distinct NF-kappa B/rel DNA binding activities in myelomonoblastic cells. J Virol (1993) 1.03
The interferon-inducible protein kinase PKR modulates the transcriptional activation of immunoglobulin kappa gene. J Biol Chem (1995) 1.03
Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeat are required for efficient viral gene transcription. J Mol Biol (1997) 1.01
Induction of monocytic differentiation and NF-kappa B-like activities by human immunodeficiency virus 1 infection of myelomonoblastic cells. J Exp Med (1992) 1.01
Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain. Oncogene (1995) 1.01
Diminution of CD4 surface protein but not CD4 messenger RNA levels in monocytic cells infected by HIV-1. AIDS (1991) 1.00
Identification by in vivo genomic footprinting of a transcriptional switch containing NF-kappaB and Sp1 that regulates the IkappaBalpha promoter. Mol Cell Biol (1999) 1.00
The role of the C-terminal domain of I kappa B alpha in protein degradation and stabilization. J Biol Chem (1996) 1.00
Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses. Differential induction of interleukin 6 and tumor necrosis factor-alpha. J Clin Invest (1992) 1.00
Inhibition of tumor necrosis factor-alpha transcription by Epstein-Barr virus. Eur J Immunol (1991) 1.00
Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene (2006) 0.99
Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst (1991) 0.99
Constitutive phosphorylation and turnover of I kappa B alpha in human T-cell leukemia virus type I-infected and Tax-expressing T cells. J Virol (1995) 0.98
Disruption of I kappa B alpha regulation by antisense RNA expression leads to malignant transformation. Oncogene (1994) 0.97
Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet (1990) 0.97
Retinoic acid is able to induce interferon regulatory factor 1 in squamous carcinoma cells via a STAT-1 independent signalling pathway. Cell Growth Differ (1999) 0.97
Autoimmune enteropathy. Pediatr Dev Pathol (1999) 0.97
Dysplasia: a common finding in intractable pediatric temporal lobe epilepsy. Neurology (2003) 0.95
Activation of cytokine genes in HIV-1 infected myelomonoblastic cells by phorbol ester and tumor necrosis factor. J Immunol (1992) 0.95
NF-kappa B activity in T cells stably expressing the Tax protein of human T cell lymphotropic virus type I. Virology (1991) 0.95
Tyrosine kinase and MAPK inhibition of TNF-alpha- and EGF-stimulated IEC-6 cell growth. Biochem Biophys Res Commun (1998) 0.95
Susceptibility to FAS-induced apoptosis in human nontumoral enterocytes: role of costimulatory factors. J Cell Physiol (1999) 0.94
Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther (2011) 0.94
Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol (1998) 0.93
Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-gamma. Eur J Immunol (1997) 0.93
Subcellular redistribution of HTLV-1 Tax protein by NF-kappa B/Rel transcription factors. Virology (1994) 0.92
Activation of the I kappa B alpha kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR. Oncogene (2001) 0.92
Effects of interferon gamma on growth, apoptosis, and MHC class II expression of immature rat intestinal crypt (IEC-6) cells. J Cell Physiol (1998) 0.92
TNFalpha-induced IEC-6 cell apoptosis requires activation of ICE caspases whereas complete inhibition of the caspase cascade leads to necrotic cell death. Biochem Biophys Res Commun (1999) 0.92
Characterization of TH3, an induction-specific protein interacting with the interferon beta promoter. Virology (1992) 0.92
Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin Exp Immunol (2003) 0.92
Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR. J Virol (1997) 0.91
Increased permeability to polyethylene glycol 4000 in rabbits with experimental colitis. Gastroenterology (1986) 0.90
Susceptibility loci reported in genome-wide association studies are associated with Crohn's disease in Canadian children. Aliment Pharmacol Ther (2010) 0.90
Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2. Oncogene (1999) 0.90